MARKSANS

Marksans Pharma Limited

Pharmaceutical products manufacturer and marketer through global subsidiaries

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

marksanspharma.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹311.00
Market cap
14,086 Cr
Stock P/E
27.3
P/B
4.66
Dividend yield
0.3%
ROE (FY26)
13.7%
ROCE (FY26)
19.0%
Operating margin (FY26)
17.0%
Debt / equity (FY26)
0.0098
OCF / EBITDA (FY26)
76.3%
OCF / EBITDA (3Y)
56.4%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Marksans (Marksans Pharma) makes generic medicines, mostly over-the-counter (OTC) products with a smaller prescription (Rx) share, and sells them mainly in the US and North America, the UK and Europe, and Australia and New Zealand.

Company snapshot

38thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Debt-to-equity of 0.01x — the company is largely funded by its own money, not borrowed funds.
1 more signal from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales531 Cr586 Cr560 Cr591 Cr642 Cr682 Cr708 Cr620 Cr720 Cr754 Cr856 Cr841 Cr
Operating expenses (approx.)417 Cr453 Cr450 Cr462 Cr506 Cr543 Cr583 Cr520 Cr576 Cr594 Cr661 Cr628 Cr
EBITDA114 Cr133 Cr110 Cr128 Cr136 Cr139 Cr126 Cr100 Cr144 Cr161 Cr195 Cr213 Cr
OPM %21.4%22.7%19.6%21.7%21.1%20.4%17.8%16.1%20.1%21.3%22.8%25.3%
Other income19 Cr5 Cr17 Cr15 Cr11 Cr28 Cr17 Cr6 Cr22 Cr20 Cr35 Cr25 Cr
Interest2 Cr3 Cr5 Cr3 Cr3 Cr3 Cr3 Cr6 Cr6 Cr6 Cr6 Cr7 Cr
Depreciation18 Cr22 Cr21 Cr20 Cr20 Cr21 Cr23 Cr23 Cr27 Cr24 Cr24 Cr25 Cr
Profit before tax114 Cr113 Cr100 Cr120 Cr125 Cr143 Cr116 Cr77 Cr133 Cr151 Cr200 Cr207 Cr
Tax %26.3%26.4%22.6%25.8%21.5%26.7%21.9%24.0%25.6%24.5%25.5%22.8%
Net profit84 Cr83 Cr78 Cr89 Cr98 Cr105 Cr91 Cr58 Cr99 Cr114 Cr149 Cr159 Cr
EPS (₹)₹1.84₹1.84₹1.73₹1.96₹2.13₹2.31₹2.00₹1.29₹2.17₹2.50₹3.27₹3.47

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales767 Cr913 Cr1,000 Cr1,134 Cr1,376 Cr1,491 Cr1,852 Cr2,177 Cr2,623 Cr2,951 CrSign in free for the trailing twelve months
Operating expenses (approx.)722 Cr826 Cr868 Cr942 Cr1,037 Cr1,232 Cr1,513 Cr1,719 Cr2,094 Cr2,350 CrSign in free for the trailing twelve months
EBITDA45 Cr86 Cr132 Cr192 Cr340 Cr259 Cr339 Cr459 Cr529 Cr601 CrSign in free for the trailing twelve months
OPM %5.8%9.5%13.2%17.0%24.7%17.4%18.3%21.1%20.2%20.4%Sign in free for the trailing twelve months
Other income7 Cr0.35 Cr5 Cr0.33 Cr7 Cr42 Cr59 Cr50 Cr70 Cr83 CrSign in free for the trailing twelve months
Interest7 Cr10 Cr10 Cr9 Cr8 Cr8 Cr9 Cr11 Cr12 Cr24 CrSign in free for the trailing twelve months
Depreciation30 Cr27 Cr23 Cr27 Cr36 Cr45 Cr52 Cr74 Cr83 Cr99 CrSign in free for the trailing twelve months
Profit before tax15 Cr50 Cr104 Cr157 Cr302 Cr248 Cr338 Cr424 Cr504 Cr561 CrSign in free for the trailing twelve months
Tax %23.9%28.1%22.9%23.2%21.1%24.5%21.4%25.6%24.1%25.1%Sign in free for the trailing twelve months
Net profit11 Cr36 Cr80 Cr121 Cr239 Cr187 Cr265 Cr315 Cr383 Cr420 CrSign in free for the trailing twelve months
EPS (₹)₹0.22₹0.80₹1.87₹2.86₹5.76₹4.51₹6.41₹6.92₹8.40₹9.22Sign in free for the trailing twelve months
Dividend payout %————1.7%5.7%3.8%7.2%7.7%8.6%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital41 Cr41 Cr41 Cr41 Cr41 Cr41 Cr45 Cr45 Cr45 Cr45 Cr
Reserves393 Cr430 Cr502 Cr595 Cr846 Cr1,161 Cr1,700 Cr2,020 Cr2,422 Cr2,978 Cr
Borrowings110 Cr117 Cr100 Cr19 Cr19 Cr41 Cr42 Cr29 Cr23 Cr30 Cr
Other liabilities202 Cr131 Cr151 Cr229 Cr304 Cr376 Cr384 Cr566 Cr727 Cr779 Cr
Total liabilities752 Cr729 Cr804 Cr897 Cr1,228 Cr1,640 Cr2,190 Cr2,681 Cr3,240 Cr3,861 Cr
Fixed assets (net)165 Cr186 Cr198 Cr220 Cr234 Cr342 Cr380 Cr676 Cr579 Cr625 Cr
CWIP0.36 Cr———6 Cr0.69 Cr7 Cr5 Cr9 Cr15 Cr
Investments——0 Cr0 Cr0 Cr0.43 Cr0.54 Cr27 Cr0.74 Cr0 Cr
Inventories190 Cr218 Cr293 Cr242 Cr404 Cr424 Cr485 Cr618 Cr846 Cr972 Cr
Trade receivables248 Cr177 Cr177 Cr243 Cr271 Cr395 Cr417 Cr453 Cr540 Cr645 Cr
Cash & bank25 Cr40 Cr34 Cr94 Cr212 Cr349 Cr382 Cr403 Cr496 Cr634 Cr
Other assets124 Cr108 Cr102 Cr98 Cr100 Cr129 Cr519 Cr498 Cr769 Cr970 Cr
Total assets752 Cr729 Cr804 Cr897 Cr1,228 Cr1,640 Cr2,190 Cr2,681 Cr3,240 Cr3,861 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity14 Cr59 Cr27 Cr210 Cr179 Cr99 Cr237 Cr230 Cr207 Cr458 Cr
Cash from investing-21 Cr-39 Cr-13 Cr-60 Cr-45 Cr-42 Cr-259 Cr-141 Cr-49 Cr-248 Cr
Cash from financing-3 Cr-5 Cr-21 Cr-90 Cr-15 Cr80 Cr198 Cr-69 Cr-65 Cr-71 Cr
Net cash flow-10 Cr15 Cr-7 Cr60 Cr119 Cr137 Cr176 Cr21 Cr93 Cr138 Cr
Free cash flow (OCF − Capex)-14 Cr20 Cr14 Cr150 Cr132 Cr53 Cr184 Cr22 Cr34 Cr328 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %3.9%10.0%17.5%24.8%33.6%20.2%19.2%20.6%20.5%19.0%
ROE %2.6%7.5%13.8%18.6%26.3%15.3%15.0%15.1%15.4%13.7%
Debtor days117716478729682767580
Inventory days189228259238351286288338409369
Days payable1617094103146135137147148128
Cash conversion cycle146228230213276247233267336321
OCF / EBITDA %31.4%68.1%20.7%109.2%52.6%38.3%70.0%50.2%39.1%76.3%
OCF / EBITDA % (3 years)——38.1%72.1%62.7%61.7%55.0%53.7%50.8%56.4%
Debt / equity0.250.250.180.030.020.030.020.010.00940.0098
Current ratio1.631.932.282.693.023.374.914.784.625.17
Net debt / EBITDA1.89—0.50-0.39-0.57-1.19-1.00-0.82-0.89-1.01